Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Nov;70(11):7561–7568. doi: 10.1128/jvi.70.11.7561-7568.1996

Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

M J Hosie 1, J N Flynn 1
PMCID: PMC190824  PMID: 8892875

Abstract

Whole inactivated virus (WIV) vaccines derived from the FL4 cell line protect cats against challenge with feline immunodeficiency virus (FIV). To investigate the correlates of protective immunity induced by WIV, we established an immunization regimen which protected a proportion of the vaccinates against challenge. A strong correlation was observed between high virus neutralizing antibody titers and protection following challenge. To investigate further the immune mechanisms responsible for immunity, all of the vaccinates were rechallenged 35 weeks following the initial challenge. Results of virus isolation from peripheral blood mononuclear cells indicated that 9 of 10 vaccinates were protected from viremia following the second challenge, suggesting that vaccine-induced immunity to FIV persisted for at least 8 months. However, more stringent analysis for evidence of infection revealed that 5 of 10 vaccinates harbored virus in lymphoid tissues. Unlike the protection observed immediately following vaccination, which correlated positively with virus neutralizing antibody titer, the ability to resist a second challenge with FIV was more closely correlated with the induction of Env-specific cytotoxic T-cell activity. The results indicate that both virus-specific humoral immunity and cellular immunity play a role in the protection induced in cats by WIV immunization but their relative importance may be dependent on the interval between vaccination and exposure to virus.

Full Text

The Full Text of this article is available as a PDF (218.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur L. O., Bess J. W., Jr, Urban R. G., Strominger J. L., Morton W. R., Mann D. L., Henderson L. E., Benveniste R. E. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol. 1995 May;69(5):3117–3124. doi: 10.1128/jvi.69.5.3117-3124.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avrameas A., Guillet J. G., Chouchane L., Moraillon A., Sonigo P., Strosberg A. D. Localisation of three epitopes of the env protein of feline immunodeficiency virus. Mol Immunol. 1992 May;29(5):565–572. doi: 10.1016/0161-5890(92)90192-z. [DOI] [PubMed] [Google Scholar]
  3. Beatty J. A., Willett B. J., Gault E. A., Jarrett O. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J Virol. 1996 Sep;70(9):6199–6206. doi: 10.1128/jvi.70.9.6199-6206.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994 Sep;68(9):6103–6110. doi: 10.1128/jvi.68.9.6103-6110.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bryson Y. J., Pang S., Wei L. S., Dickover R., Diagne A., Chen I. S. Clearance of HIV infection in a perinatally infected infant. N Engl J Med. 1995 Mar 30;332(13):833–838. doi: 10.1056/NEJM199503303321301. [DOI] [PubMed] [Google Scholar]
  6. Carlson J. R., McGraw T. P., Keddie E., Yee J. L., Rosenthal A., Langlois A. J., Dickover R., Donovan R., Luciw P. A., Jennings M. B. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1239–1246. doi: 10.1089/aid.1990.6.1239. [DOI] [PubMed] [Google Scholar]
  7. Cheynier R., Langlade-Demoyen P., Marescot M. R., Blanche S., Blondin G., Wain-Hobson S., Griscelli C., Vilmer E., Plata F. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol. 1992 Sep;22(9):2211–2217. doi: 10.1002/eji.1830220905. [DOI] [PubMed] [Google Scholar]
  8. Clements J. E., Montelaro R. C., Zink M. C., Amedee A. M., Miller S., Trichel A. M., Jagerski B., Hauer D., Martin L. N., Bohm R. P. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol. 1995 May;69(5):2737–2744. doi: 10.1128/jvi.69.5.2737-2744.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Crandell R. A., Fabricant C. G., Nelson-Rees W. A. Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). In Vitro. 1973 Nov-Dec;9(3):176–185. doi: 10.1007/BF02618435. [DOI] [PubMed] [Google Scholar]
  10. Desrosiers R. C., Wyand M. S., Kodama T., Ringler D. J., Arthur L. O., Sehgal P. K., Letvin N. L., King N. W., Daniel M. D. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6353–6357. doi: 10.1073/pnas.86.16.6353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., Haase A. T. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993 Mar 25;362(6418):359–362. doi: 10.1038/362359a0. [DOI] [PubMed] [Google Scholar]
  12. Flynn J. N., Beatty J. A., Cannon C. A., Stephens E. B., Hosie M. J., Neil J. C., Jarrett O. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus. AIDS Res Hum Retroviruses. 1995 Sep;11(9):1107–1113. doi: 10.1089/aid.1995.11.1107. [DOI] [PubMed] [Google Scholar]
  13. Flynn J. N., Cannon C. A., Beatty J. A., Mackett M., Rigby M. A., Neil J. C., Jarrett C. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide. J Virol. 1994 Sep;68(9):5835–5844. doi: 10.1128/jvi.68.9.5835-5844.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Flynn J. N., Cannon C. A., Reid G., Rigby M. A., Neil J. C., Jarrett O. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology. 1995 Jun;85(2):171–175. [PMC free article] [PubMed] [Google Scholar]
  15. Heath S. L., Tew J. G., Tew J. G., Szakal A. K., Burton G. F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature. 1995 Oct 26;377(6551):740–744. doi: 10.1038/377740a0. [DOI] [PubMed] [Google Scholar]
  16. Hohdatsu T., Pu R., Torres B. A., Trujillo S., Gardner M. B., Yamamoto J. K. Passive antibody protection of cats against feline immunodeficiency virus infection. J Virol. 1993 Apr;67(4):2344–2348. doi: 10.1128/jvi.67.4.2344-2348.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hosie M. J., Dunsford T. H., de Ronde A., Willett B. J., Cannon C. A., Neil J. C., Jarrett O. Suppression of virus burden by immunization with feline immunodeficiency virus Env protein. Vaccine. 1996 Apr;14(5):405–411. doi: 10.1016/0264-410x(95)00193-5. [DOI] [PubMed] [Google Scholar]
  18. Hosie M. J., Osborne R., Yamamoto J. K., Neil J. C., Jarrett O. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol. 1995 Feb;69(2):1253–1255. doi: 10.1128/jvi.69.2.1253-1255.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Johnson C. M., Torres B. A., Koyama H., Yamamoto J. K. Tenth anniversary perspectives on AIDS. FIV as a model for AIDS vaccination. AIDS Res Hum Retroviruses. 1994 Mar;10(3):225–228. doi: 10.1089/aid.1994.10.225. [DOI] [PubMed] [Google Scholar]
  20. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650–4655. doi: 10.1128/jvi.68.7.4650-4655.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lombardi S., Garzelli C., La Rosa C., Zaccaro L., Specter S., Malvaldi G., Tozzini F., Esposito F., Bendinelli M. Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol. 1993 Aug;67(8):4742–4749. doi: 10.1128/jvi.67.8.4742-4749.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., da Prato L., Bandecchi P., Tozzini F. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol. 1994 Dec;68(12):8374–8379. doi: 10.1128/jvi.68.12.8374-8379.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Del Mauro D., Zaccaro L., Bandecchi P., Tozzini F., Bendinelli M. Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol. 1996 Jan;70(1):617–622. doi: 10.1128/jvi.70.1.617-622.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Miyazawa T., Furuya T., Itagaki S., Tohya Y., Takahashi E., Mikami T. Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus. Arch Virol. 1989;108(1-2):131–135. doi: 10.1007/BF01313750. [DOI] [PubMed] [Google Scholar]
  25. Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J. Y., Putney S. D. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989 Dec 8;246(4935):1293–1297. doi: 10.1126/science.2555923. [DOI] [PubMed] [Google Scholar]
  26. Newell M. L., Dunn D., De Maria A., Ferrazin A., De Rossi A., Giaquinto C., Levy J., Alimenti A., Ehrnst A., Bohlin A. B. Detection of virus in vertically exposed HIV-antibody-negative children. Lancet. 1996 Jan 27;347(8996):213–215. doi: 10.1016/s0140-6736(96)90401-8. [DOI] [PubMed] [Google Scholar]
  27. Nixon D. F., Broliden K., Ogg G., Broliden P. A. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology. 1992 Aug;76(4):515–534. [PMC free article] [PubMed] [Google Scholar]
  28. Nixon D. F., Townsend A. R., Elvin J. G., Rizza C. R., Gallwey J., McMichael A. J. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988 Dec 1;336(6198):484–487. doi: 10.1038/336484a0. [DOI] [PubMed] [Google Scholar]
  29. Osborne R., Rigby M., Siebelink K., Neil J. C., Jarrett O. Virus neutralization reveals antigenic variation among feline immunodeficiency virus isolates. J Gen Virol. 1994 Dec;75(Pt 12):3641–3645. doi: 10.1099/0022-1317-75-12-3641. [DOI] [PubMed] [Google Scholar]
  30. Pantaleo G., Demarest J. F., Soudeyns H., Graziosi C., Denis F., Adelsberger J. W., Borrow P., Saag M. S., Shaw G. M., Sekaly R. P. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 1994 Aug 11;370(6489):463–467. doi: 10.1038/370463a0. [DOI] [PubMed] [Google Scholar]
  31. Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993 Mar 25;362(6418):355–358. doi: 10.1038/362355a0. [DOI] [PubMed] [Google Scholar]
  32. Rowland-Jones S. L., Nixon D. F., Aldhous M. C., Gotch F., Ariyoshi K., Hallam N., Kroll J. S., Froebel K., McMichael A. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 1993 Apr 3;341(8849):860–861. doi: 10.1016/0140-6736(93)93063-7. [DOI] [PubMed] [Google Scholar]
  33. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., Corrah T. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995 Jan;1(1):59–64. doi: 10.1038/nm0195-59. [DOI] [PubMed] [Google Scholar]
  34. Sethi K. K., Näher H., Stroehmann I. Phenotypic heterogeneity of cerebrospinal fluid-derived HIV-specific and HLA-restricted cytotoxic T-cell clones. Nature. 1988 Sep 8;335(6186):178–181. doi: 10.1038/335178a0. [DOI] [PubMed] [Google Scholar]
  35. Sibille P., Avraméas A., Moraillon A., Richardson J., Sonigo P., Pancino G., Strosberg A. D. Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats. Vet Microbiol. 1995 Jul;45(2-3):259–267. doi: 10.1016/0378-1135(94)00128-j. [DOI] [PubMed] [Google Scholar]
  36. Siebelink K. H., Rimmelzwaan G. F., Bosch M. L., Meloen R. H., Osterhaus A. D. A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol. 1993 Apr;67(4):2202–2208. doi: 10.1128/jvi.67.4.2202-2208.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Stephens E. B., Butfiloski E. J., Monck E. Analysis of the amino terminal presequence of the feline immunodeficiency virus glycoprotein: effect of deletions on the intracellular transport of gp95. Virology. 1992 Oct;190(2):569–578. doi: 10.1016/0042-6822(92)90894-u. [DOI] [PubMed] [Google Scholar]
  38. Stott E. J. Anti-cell antibody in macaques. Nature. 1991 Oct 3;353(6343):393–393. doi: 10.1038/353393a0. [DOI] [PubMed] [Google Scholar]
  39. Willett B. J., Hosie M. J., Dunsford T. H., Neil J. C., Jarrett O. Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4. AIDS. 1991 Dec;5(12):1469–1475. doi: 10.1097/00002030-199112000-00009. [DOI] [PubMed] [Google Scholar]
  40. Wyand M. S., Manson K. H., Garcia-Moll M., Montefiori D., Desrosiers R. C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol. 1996 Jun;70(6):3724–3733. doi: 10.1128/jvi.70.6.3724-3733.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yamamoto J. K., Ackley C. D., Zochlinski H., Louie H., Pembroke E., Torten M., Hansen H., Munn R., Okuda T. Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology. 1991;32(6):361–375. doi: 10.1159/000150220. [DOI] [PubMed] [Google Scholar]
  42. Yamamoto J. K., Hohdatsu T., Olmsted R. A., Pu R., Louie H., Zochlinski H. A., Acevedo V., Johnson H. M., Soulds G. A., Gardner M. B. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol. 1993 Jan;67(1):601–605. doi: 10.1128/jvi.67.1.601-605.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Yamamoto J. K., Okuda T., Ackley C. D., Louie H., Pembroke E., Zochlinski H., Munn R. J., Gardner M. B. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retroviruses. 1991 Nov;7(11):911–922. doi: 10.1089/aid.1991.7.911. [DOI] [PubMed] [Google Scholar]
  44. Zinkernagel R. M., Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today. 1994 Jun;15(6):262–268. doi: 10.1016/0167-5699(94)90005-1. [DOI] [PubMed] [Google Scholar]
  45. van Baalen C. A., Klein M. R., Geretti A. M., Keet R. I., Miedema F., van Els C. A., Osterhaus A. D. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS. 1993 Jun;7(6):781–786. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES